本研究分析了 3 项研究,共计 309 例接受第一代或第二代 EGFR TKI 治疗后出现疾病进展的 E746_A750del 或罕见亚型患者,以比较获得性 T790M 突变的频率。相比于不常见亚型,E746_A750del 组患者在第一代或第二代 EGFR TKI 治疗出现...
金融界12月11日消息，迪哲医药自主研发的新型肺癌靶向药舒沃哲®的一项I/II期临床研究的汇总分析最新数据发表于欧洲肿瘤内科学会官方期刊《Lung Cancer》。舒沃哲®于2023年8月在国内获批上市，是目前表皮生长因子受体20号外显子插入突变非小细胞肺癌二/后线唯一标准治疗方案。此次数据来自舒沃哲®3项国内外I...
LM确诊后接受EGFR TKI治疗的患者OS长于未接受EGFR TKI治疗的患者(9.5个月vs 1.7个月,P<0.001)。如下表所示,伴中枢神经系统转移的NSCLC患者可能从EGFR-TKI和PARP抑制剂和EGFR-TKI联合治疗中获益。但仍需更多研究证明多靶点治疗组合的有效...
EGFR is one of the human epidermal growth factor receptor (HER) family proteins, and signaling intermediated by EGFR has received intense focus, resulting in the emergence of attractive candidates for anticancer therapy, especially in lung cancer. In this section, we focus on the signaling cascade...
Lung cancer is the leading global cause of cancer-related mortality. Inter-individual variability in treatment response and prognosis has been associated w... JG Carneiro,PG Couto,L Bastos-Rodrigues,... - 《Genetics Research》 被引量: 33发表: 2014年 Roles of EGFR and KRAS Mutations in the ...
We show the evolution of a case ofEGFRmutant lung cancer treated with a combination of erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine targeting somatic mutations, includingEGFRexon 19 deletion. Maise Al Bakir James L. Reading ...
EGFR突变可切除的NSCLC围手术期辅助靶向治疗研究进展及问题探讨 肺癌在全球范围内仍是导致癌症死亡的首要原因,非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌的主要病理类型,占80%左右.在所有NSCLC患者中,约30%初诊时为可切... 宋朋,崔永 - 《中国肺癌杂志》 被引量: 0发表: 2024年 Real‐world data...
今日(12月11日),迪哲药业官网在其官网宣布,舒沃替尼(商品名舒沃哲®)单药治疗EGFR突变的非小细胞肺癌患者的临床I/II期研究的汇总分析最新数据发表于欧洲肿瘤内科学会(ESMO)官方期刊《Lung Cancer》,本次汇总分析涵盖WU-KONG1(NCT03974022),WU-KONG2(CTR20192097)and WU-KONG15(NCT05559645)三项临床研究。舒...
EGFR inhibition is an effective treatment in the minority of non-small cell lung cancer (NSCLC) cases harboring EGFR-activating mutations, but not in EGFR wild-type (EGFRwt) tumors. Here we demonstrate that EGFR inhibition triggers an antiviral defense pathway in NSCLC. Inhibiting mutant EGFR tr...
Lung cancer: A new generation of EGFR inhibition EGFR inhibitors result in excellent tumour responses and prolonged progression-free survival (PFS) in patients with advanced-stage, EGFR -mutant non-small-cell lung cancer (NSCLC); however, acquired resistance is a huge challenge, and mi......